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Edited by Masayuki MiyasakaAbstract Angiopoietin-1 (Ang-1) is known to have hematopro-
tective eﬀects by increasing the quiescence of hematopoietic stem
cells. However, it remains to be determined if the upregulation of
Ang-1 and the subsequent increase in the quiescence of hemato-
poietic stem cells are also involved in the dexamethasone (Dex)-
mediated bone marrow protection. Here Western blotting and
ﬂow cytometric analyses demonstrate that Dex increases the lev-
els of Ang-1 in mouse bone marrow and the quiescence of hema-
topoietic stem cells. Our data for the ﬁrst time suggest that the
increased quiescence of hematopoietic stem cells provides a novel
mechanism of Dex-induced hematoprotection.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hematopoietic suppression is the major dose-limiting toxic-
ity of many anticancer chemotherapy agents [1]. Glucocorti-
coid pretreatment has been shown to protect hematopoietic
stem cells (HSCs) from bone marrow-suppressing chemother-
apy in mice [2] and humans [3]. It remains unknown if gluco-
corticoids increase quiescent HSCs that are more invulnerable
to chemotherapeutic agent.
Tie-2 is a receptor tyrosine kinase expressed on endothelial
cells and HSCs [4,5]. Angiopoietins (Angs) are ligands for
Tie-2 and relatively little is known about Ang-3 and -4 [6].Abbreviations: Dex, dexamethasone; Dex-P, dexamethasone-21-phos-
phate; Ang-1, angiopoietin-1; Ang-2, angiopoietin-2; GR, glucocorti-
coid receptor; GRE, glucocorticoid responsive element; HSCs,
hematopoietic stem cells; LSK, LinSca-1+c-kit+; MNCs, mononu-
clear cells; MSCs, mesenchymal stem cells; SP, side population; VEGF,
vascular endothelial growth factor
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doi:10.1016/j.febslet.2008.09.021Angiopoietin-1 (Ang-1) is a well known agonist for Tie-2,
whereas Angiopoietin-2 (Ang-2) acts as an antagonist in the
context of the endothelial cells [7]. In hematopoietic cells,
Ang-1 eﬀectively induces phosphorylation of Tie-2 as an ago-
nist, whereas Ang-2 weakens the phosphorylation induced by
Ang-1 although Ang-2 also induces a low level of phosphory-
lation of Tie-2 in the absence of Ang-1 [8]. Arai et al. reported
that exogenous Ang-1 treatment protected bone marrow from
5-ﬂuorouracil, a chemotherapeutic agent, by increasing the
quiescent HSCs that are more resistant to cytotoxic chemo-
therapy [9]. However, it is yet unknown if the Ang-1/Tie2 sig-
naling pathway and the subsequent increase in quiescent HSCs
are also associated with glucocorticoid-mediated hematopro-
tection during cytotoxic chemotherapy.
Here, we show that intraperitoneal injection of dexametha-
sone (Dex, a synthetic glucocorticoid) upregulated Ang-1
expression in mouse bone marrow and increased a quiescent
subset of HSCs. Thus, to our knowledge, Dex is the ﬁrst small
molecule reported to increase the quiescence of HSCs in bone
marrow.2. Materials and methods
2.1. Dex treatment in mice and harvest of the bone marrow
All animal experimental procedures were carried out in accordance
with the Guidelines and Regulations for the Use and Care of Animals
of the National Institute of Health in Korea. C57/BL6 mice (7–8 weeks
old) were intraperitoneally injected with dexamethasone-21-phosphate
(Dex-P, 0.1 mg/kg/day), which is converted to active Dex in vivo [10],
every 12 h for 30 h (total three injections). The bone marrow was har-
vested by ﬂushing the femurs and tibia using PBS (phosphate buﬀered
saline without calcium and magnesium).
From the isolated bone marrow, total bone marrow nucleated cells
were obtained by lysing red blood cells using red blood cell lysis buﬀer
(Roche Applied Science, Indianapolis, IN) and mononuclear cell
(MNC) fraction was isolated using Ficoll-paque Plus (GE Health-
care Bio-Sciences AB, Uppsala, Sweden) according to the manufac-
turers instruction.
2.2. Flow cytometric analysis
All antibodies used for ﬂow cytometric analysis were from BD bio-
science (San Jose, CA), and all ﬂow cytometric analyses and sorting
were performed using a FACSVantage (BD Biosciences). To isolate
CD45+ and CD45 cells, total nucleated cells were stained withblished by Elsevier B.V. All rights reserved.
Fig. 1. Dex increases the level of Ang-1 in mouse bone marrow.
C57/BL6 mice were intraperitoneally injected with Dex-P (0.1 mg/kg/
day) every 12 h for 30 h (total three injections). (A) The whole bone
marrow was then isolated and subjected to Western blotting analysis to
determine the levels of Ang-1. Dex-P increased Ang-1 protein. (B) The
bone marrow nucleated cells were sorted using CD45, panhematopoi-
etic cell marker, into two groups (CD45+ and CD45 cells) and
subjected to Western blotting analysis to examine the levels of Ang-1.
Dex increased Ang-1 levels only in CD45 cells, whereas the
expression of Ang-1 was barely detected in CD45+ cells.
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mine LinSca-1+c-kit+ (LSK) cells, MNCs were stained using APC-
conjugated anti-c-kit, PE-conjugated anti-Sca-1, and biotinylated
anti-lineage (followed by staining with streptavidine-PerCP-Cy5.5)
antibodies at 4 C for 30 min, washed and analyzed. The cell-cycle sta-
tus of LSK cells was determined as previously described [11]. Brieﬂy,
LSK cells were sorted, ﬁxed with BD Cytoﬁx/Cytoperm buﬀer (BD
Biosciences), and washed with BD Perm/Wash buﬀer (BD Biosci-
ences). Cells were stained with FITC-conjugated anti-Ki-67 antibody
in EFPBS (PBS supplemented with 5 mM EDTA and 2% fetal bovine
serum, pH 7.4) at room temperature for 30 min, washed, resuspended
in EFPBS containing 5 lg/ml of 7-aminoactinomycin-D (7-AAD), and
analyzed. To identify CD34 LSK cells, MNCs were stained with
APC-conjugated anti-c-kit, PE-conjugated anti-Sca-1, biotinylated
anti-lineage (followed by streptavidine-PerCP-Cy5.5), and FITC-con-
jugated anti-CD34 antibodies at 4 C for 30 min, washed and ana-
lyzed. The side population (SP) cells among LSK cells (LSK-SP)
were determined as previously described [12]. Brieﬂy, MNCs were
stained with 1 lg/ml Hoechst (Sigma) at 106 cells/ml for 90 min at
37 C. Cells were resuspended at 107 cells/ml, stained with anti-c-kit,
anti-Sca-1, and anti-linage antibodies at 4 C, and analyzed. Vital
staining was carried out using 7-AAD (BD Pharmingen). Cells treated
with 50 lM verapamil (Sigma–Aldrich) during the entire Hoechst
staining procedure served as control to determine SP cells.
2.3. Culture and Dex treatment of human mesenchymal stem cells
(MSCs)
Human MSCs were purchased from Cambrex BioScience (Walkers-
ville, MD), cultured in complete media which consisted of Dulbeccos
Modiﬁed Eagles Media (low glucose) containing 20% fetal bovine ser-
um (Invitrogen corporation, Grand Island, NY) as previously de-
scribed [13]. Human MSCs were stimulated with various
concentrations of Dex or solvent control (0.05% DMSO) for 24 h or
indicated times.
2.4. Determination of Ang-1 levels in mouse bone marrow and human
MSCs
The levels of Ang-1 protein in the bone marrow, CD45+ and CD45
bone marrow cells were measured by Western blotting analysis using
anti-Ang-1 antibody (Abcam, Cambridge, UK) as previously described
[14]. The concentrations of Ang-1 and Ang-2 in culture supernatants
from human MSCs were determined using ELISA kits (R&D Systems
Inc., Minneapolis, MN). To determine Ang-1 mRNA, total RNA was
isolated with Trizol and subjected to quantitative real-time RT-PCR
analysis as previously described [13] using the following primers: for
human Ang-1, forward 5 0-GGAAGGGAACCGAGCCTATT-30,
reverse 5 0-TTCCTGCTGTCCCAGTGTGA-3 0; for human b-actin,
forward 5 0-GCCCAGTCCTCTCCCAAGTC-3 0, reverse 5 0-GGCAC-
GAAGGCTCATCATTC-3 0.
2.5. mRNA stability assay
To determine the stability of the Ang-1 mRNA, human MSCs were
exposed to 100 nM Dex for 24 h, after which actinomycin D (10 lg/ml)
was added to stop the RNA synthesis [15]. Total RNA was isolated at
the indicated times and subjected to real-time RT-PCR.
2.6. Promoter activity assay
The Ang-1 promoter (3040/+199) construct was kindly provided by
Dr. Peter Oettgen (Harvard Institutes of Medicine, Boston, MA) and
the promoter activities were determined as previously described [14].
2.7. Actinomycin D inhibition test
One hour after pretreatment with 10 lg/ml actinomycin D, cells were
treated with 100 nM Dex or solvent control (0.05% DMSO) for 24 h in
the presence of actinomycin D. Total RNA was isolated and subjected
to real-time RT-PCR as described above.
2.8. Statistical analysis
All values are presented as the mean ± standard error (S.E.). Signif-
icance was determined by a Students t-test or ANOVA followed by
multiple comparisons by Tukeys test using SPSS for Windows (SPSS
Inc., Chicago, IL). A P value of <0.05 was considered to be statistically
signiﬁcant.3. Results and discussion
3.1. Expression and regulation of Ang-1 by Dex in mouse bone
marrow
As Ang-1 has been reported to play a pivotal role in hemat-
oprotection [9], we investigated if Dex increases the level of
Ang-1 in mouse bone marrow. Intraperitoneal Dex-P in-
creased the level of Ang-1 protein in mouse bone marrow
in vivo (Fig. 1A). To further determine which subset of cells
is responsible for Dex-induced Ang-1 upregulation, we sorted
total bone marrow nucleated cells using a pan-hematopoietic
cell marker, CD45, which detects all hematopoietic cells. As
shown in Fig. 1B, Ang-1 was detected only in CD45 cells,
indicating that non-hematopoietic cells are the main producer
of Ang-1 in bone marrow. This is compatible with previous re-
ports that Ang-1 is mainly produced by non-hematopoietic
cells such as osteoblasts [9] or self-renewing osteoprogenitor
cells [16]. In contrast, Ang-1 was barely detected in CD45+
cells. Moreover, when mice were treated with Dex-P, the
Ang-1 levels increased only in CD45 cells, suggesting that
Dex increases Ang-1 in non-hematopoietic cells.
3.2. Dex increases quiescent HSCs in mouse bone marrow
As Ang-1 increases the quiescence of HSCs [9], leading to
subsequent bone marrow protection against cytotoxic chemo-
therapy, this study was aimed to examine if Dex-P also in-
creases the quiescence of HSCs in mouse bone marrow. The
number of neither total bone marrow nucleated cells nor
LSK cells was changed by Dex-P treatment (Fig. 2A–C). To
identify the quiescent HSCs among LSK cells, cells were then
stained with 7-AAD and Ki-67 antibody and the quiescent
HSCs in G0 phase were determined by ﬂow cytometric analysis
[11,17]. The percentage of cells in G0 phase among LSK cells
signiﬁcantly increased from 25.5 ± 2.0% (mean ± S.E.) to
34.2 ± 2.2% (P < 0.05, Fig. 2D and E), suggesting that Dex-P
increases the quiescence of HSCs. As quiescent HSCs can be
also identiﬁed as CD34 LSK cells [18,19], we further investi-
gated if Dex-P treatment increases CD34 cells among LSK
cells. Flow cytometric analysis revealed that CD34 cells
among LSK cells dramatically increased from 7.5 ± 1.1% to
23.7 ± 2.3% (P < 0.001, Fig. 2F and G), indicating that Dex in-
Fig. 2. Dex increases quiescent of HSCs in mouse bone marrow. (A) The number of bone marrow (BM) cells was measured by cell counting after
Dex-P treatment. The number of total nucleated cells was not changed by Dex-P treatment. (B–H) The bone marrow MNCs were isolated and
subjected to ﬂow cytometric analysis. (B) Determination of LSK cells. (C) The number of LSK cells was not changed by Dex-P treatment (n = 4). (D)
Determination of quiescent HSCs in G0 phase by Ki-67 and 7-AAD staining in LSK cells. (E) Dex-P treatment signiﬁcantly increased the percentage
of G0 cells among LSK cells (*P < 0.05, n = 6). (F) Determination of CD34 cells in LSK cells. (G) Dex-P treatment signiﬁcantly increased the
percentage of CD34 cells among LSK cells (***P < 0.001, n = 4). (H) Determination of side population (SP) and main population (MP) by Hoechst
staining. (I) Dex-P treatment signiﬁcantly increased the SP/MP ratio (*P < 0.05, n = 17–19).
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reported that SP is another marker of quiescent HSCs and that
LSK-SP is a subset of HSCs that are resistant to 5-ﬂuorouracil
which induces apoptosis in actively cycling cells [9,20], we
examined SP among LSK cells. As shown in Fig. 2H and I,
Dex-P signiﬁcantly increased the ratio of SP/MP in LSK cells
by 2.1 ± 0.5-fold compared to the PBS-treated control. Taken
all together, Dex-P treatment increased the number of quies-
cent HSCs that is more invulnerable to cytotoxic chemother-
apy, providing a novel mechanism of Dex-induced bonemarrow protection. To our knowledge, Dex is the ﬁrst small
molecule that has been identiﬁed to increase the quiescence
of HSCs.
3.3. Dex increases the level of Ang-1 protein and mRNA in a
glucocorticoid receptor (GR)-dependent manner in human
MSCs
To investigate the molecular mechanism underlying Dex-in-
duced Ang-1 upregulation, we used bone marrow-derived hu-
man MSCs, the major producers of Ang-1 in bone marrow
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environment [16,21,22]. ELISA revealed that Dex increased
Ang-1 protein secretion from human MSCs in a dose-depen-
dent manner, with a maximum of 48.4 ± 7.0 pg/lg cellular pro-
tein at 100 nM Dex treatment (Fig. 3A). Although Ang-2, a
natural antagonist for Tie-2, was detected only in Dex-treated
cells, its level was 500 times less than that of Ang-1 (data not
shown). A GR antagonist RU486 completely attenuated this
eﬀect of Dex (P < 0.001) in a dose-dependent manner
(Fig. 3B), suggesting a GR-mediation. We next determined if
the increase in Ang-1 protein is attributable to an increase in
the mRNA level. Real-time RT-PCR analysis showed that
Dex increased Ang-1 mRNA levels in a dose-dependent man-
ner, with a maximal increase of 7.8 ± 1.1-fold at 100 nM
(Fig. 3C). This increase was also time-dependent, with a max-
imum increase of 6.3 ± 0.8-fold at 24 h (Fig. 3D).
Previously, it was reported that adipocytic conversion from
ﬁbroblasts is accompanied by the increased expression of Ang-
1 [23]. This previous report, together with a possibility that
Dex may induce adipogenic diﬀerentiation from hMSCs,
prompted us to investigate if the observed eﬀects depend on
Dex-derived cell diﬀerentiation. In this regard, we have re-
cently reported that Dex directly increased the levels of Ang-
1 protein and mRNA in fully diﬀerentiated cells such as human
brain pericytes and astrocytes [24]. Furthermore, we alsoFig. 3. Dex increases the levels of Ang-1 protein and mRNA in a GR-depend
control) or Dex in the absence or presence of RU486. (A and B) The conc
determined using ELISA. Each bar represents the amount of secreted Ang-1 n
in a dose-dependent manner (A). This increase was abrogated by RU486, a G
Ang-1 (B). (C and D) Total RNA was isolated using TRIzol and subjected t
Dex (C) or with 100 nM Dex for the indicated times (D) and the Ang-1 mRN
mRNA normalized to that of control. Dex increased Ang-1 mRNA in
***P < 0.001 (A, B, and D, n = 3; C, n = 5).found a signiﬁcant increase in Ang-1 mRNA by Dex treatment
in several other tissues, retina, brain cortex, and bone marrow
(data not shown). These data support our conclusion that Dex
directly increases Ang-1 independent of cell diﬀerentiation.
Furthermore, under our experimental conditions, using Oil
Red O staining we failed to ﬁnd Dex-derived adipogenic diﬀer-
entiation from hMSCs (data not shown).
3.4. Dex increases the level of Ang-1mRNA without changing
mRNA stability in human MSCs
As the increase in mRNA may have occurred as a result of
the increase in mRNA stability and/or the activation of tran-
scription, we examined which of these factors contributes to
the upregulation of Ang-1 mRNA. As shown in Fig. 4A,
Ang-1 mRNA was very stable, and the stability was not chan-
ged by Dex treatment. The high stability of Ang-1 mRNA was
previously reported in retinal pigment epithelial cells [25]. Un-
der the same experimental conditions, vascular endothelial
growth factor (VEGF) mRNA measured as a reference de-
creased rapidly (Fig. 4A, inset). We also found that Dex signif-
icantly increased the Ang-1 promoter activity by 1.9 ± 0.2-fold
(P < 0.05) (Fig. 4B), and that RU486 completely inhibited this
Dex-stimulated Ang-1 promoter activity in a dose-dependent
manner, further indicating a GR-mediation. To further con-
ﬁrm that transcriptional activation, but not alteration ofent manner. Human MSCs were stimulated with 0.05% DMSO (solvent
entrations of Ang-1 in the supernatants of human MSC culture were
ormalized to that of total cellular protein. Dex increased Ang-1 protein
R antagonist, suggesting that GR mediates the Dex-induced increase in
o real-time RT-PCR. Cells were treated for 24 h with various doses of
A levels were then determined. Each bar represents the level of Ang-1
a dose (C)- and time (D)-dependent manner. *P < 0.05, **P < 0.01,
Fig. 4. Dex increases the levels of Ang-1 mRNA through a transcriptional activation. (A) Ang-1 mRNA stability assay. Human MSC were treated
with DMSO (solvent control) or 100 nM Dex for 24 h and RNA synthesis was blocked by adding actinomycin D. Total RNA was isolated at the
indicated times after actinomycin D treatment and the levels of Ang-1 and VEGF mRNA (inset) were determined by real-time RT-PCR. Each point
represents the Ang-1 or VEGF mRNA levels normalized to the levels that were present just before the addition of actinomycin D. Ang-1 mRNA was
very stable, and this stability was not altered by Dex treatment. (B) Promoter activity assay. Human MSCs were transfected with a luciferase vector
containing Ang-1 promoter followed by treatment with Dex for 24 h and the luciferase activities of the cell lysates were then determined. Each bar
represents the promoter activity relative to the solvent control-treated group. Dex treatment increased Ang-1 promoter activity, which was
attenuated to the basal level by the addition of RU486. (C) Human MSCs were pretreated with 10 lg/ml actinomycin D or solvent control (0.05%
DMSO) for 1 h and stimulated with 100 nM Dex or solvent control in the presence or absence of actinomycin D for 24 h. Total RNA was isolated
and subjected to real-time RT-PCR to determine the Ang-1 mRNA levels. Each bar represents the Ang-1 mRNA level. Actinomycin D completely
inhibited Dex-induced Ang-1 increase. **P < 0.01, ***P < 0.001 (A, n = 9; B, n = 6–8; C, n = 7).
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treated human MSCs with Dex in the presence of actinomycin
D and found that the Dex-induced increase in Ang-1 mRNA
was completely inhibited (Fig. 4C).
3.5. Ang-1 promoter has putative glucocorticoid response
elements (GREs)
It has been shown that several proteins are induced by glu-
cocorticoids through transcriptional activation as a result of
the binding of activated GR to the GREs in the regulatory re-
gions of the genes [26–29]. Therefore, we identiﬁed putative
GREs in the Ang-1 promoter in silico using two web-based
transcription factor binding site searching programs, Match
(http://www.gene-regulation.com/pub/programs.html#match)
and MatInspector (http://www.genomatix.de/products/MatIn-
spector). MatInspector proposed 2696, 1932, and +294 re-
gions as putative GREs, all of which are also identiﬁed by
Match. Taken together, our data suggest that Dex increases
the level of Ang-1 protein in human MSCs via a transcrip-
tional activation, possibly resulting from the binding of acti-
vated GR to the putative GREs in the Ang-1 promoter.
However, the elucidation of the mechanisms by which Dex-stimulated Ang-1 expression occurs requires further experi-
ments, including nuclear run-on assay, promoter activity assay
using serially deleted promoter constructs, mutational analysis
of GREs in the Ang-1 promoter, and DNA–protein binding
assay.4. Conclusion
In summary, Dex increased Ang-1 in bone marrow and in-
creased quiescent HSCs which are invulnerable to cytotoxic
chemotherapy. Investigation of the molecular mechanism by
which Ang-1 upregulation occurred suggests that Dex in-
creases Ang-1 mRNA at the transcriptional level. Our ﬁndings
propose the increase in quiescent HSCs as a novel mechanism
of Dex-induced protection of HSCs in the setting of chemo-
therapy.
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